In three other studies, miR-31 expression was significantly associated with PFS in KRAS wild-type mCRC patients treated with anti-EGFR therapy [240,241,242], but not when the tumour was right-sided [243], and in these patients, miR-31 was also associated with the time to progression [244]. The gene discussed is KRAS; the disease is neoplasm.